150 related articles for article (PubMed ID: 15646644)
1. Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
Lin CC; Yeh LT; Vitarella D; Hong Z; Erion MD
Antivir Chem Chemother; 2004 Nov; 15(6):307-17. PubMed ID: 15646644
[TBL] [Abstract][Full Text] [Related]
2. Liver-targeted drug delivery using HepDirect prodrugs.
Erion MD; van Poelje PD; Mackenna DA; Colby TJ; Montag AC; Fujitaki JM; Linemeyer DL; Bullough DA
J Pharmacol Exp Ther; 2005 Feb; 312(2):554-60. PubMed ID: 15340017
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys.
Lin CC; Xu C; Zhu N; Lourenco D; Yeh LT
Antimicrob Agents Chemother; 2005 Mar; 49(3):925-30. PubMed ID: 15728885
[TBL] [Abstract][Full Text] [Related]
4. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Reddy KR; Matelich MC; Ugarkar BG; Gómez-Galeno JE; DaRe J; Ollis K; Sun Z; Craigo W; Colby TJ; Fujitaki JM; Boyer SH; van Poelje PD; Erion MD
J Med Chem; 2008 Feb; 51(3):666-76. PubMed ID: 18173234
[TBL] [Abstract][Full Text] [Related]
5. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.
Lin CC; Yeh LT; Vitarella D; Hong Z
Antivir Chem Chemother; 2003 May; 14(3):145-52. PubMed ID: 14521331
[TBL] [Abstract][Full Text] [Related]
6. Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
Tillmann HL
Curr Opin Investig Drugs; 2007 Aug; 8(8):682-90. PubMed ID: 17668370
[TBL] [Abstract][Full Text] [Related]
7. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.
Erion MD; Bullough DA; Lin CC; Hong Z
Curr Opin Investig Drugs; 2006 Feb; 7(2):109-17. PubMed ID: 16499280
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel oxazaphosphorine prodrugs of 9-(2-phosphonomethoxyethyl)adenine (PMEA, adefovir) as potent HBV inhibitors.
Lu P; Liu J; Wang Y; Chen X; Yang Y; Ji R
Bioorg Med Chem Lett; 2009 Dec; 19(24):6918-21. PubMed ID: 19889538
[TBL] [Abstract][Full Text] [Related]
9. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.
de Vrueh RL; Rump ET; van De Bilt E; van Veghel R; Balzarini J; Biessen EA; van Berkel TJ; Bijsterbosch MK
Antimicrob Agents Chemother; 2000 Mar; 44(3):477-83. PubMed ID: 10681306
[TBL] [Abstract][Full Text] [Related]
10. Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity.
Biessen EA; Valentijn AR; De Vrueh RL; Van De Bilt E; Sliedregt LA; Prince P; Bijsterbosch MK; Van Boom JH; Van Der Marel GA; Abrahams PJ; Van Berkel TJ
FASEB J; 2000 Sep; 14(12):1784-92. PubMed ID: 10973928
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier.
de Vrueh RL; Rump ET; Sliedregt LA; Biessen EA; van Berkel TJ; Bijsterbosch MK
Pharm Res; 1999 Aug; 16(8):1179-85. PubMed ID: 10468017
[TBL] [Abstract][Full Text] [Related]
12. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats.
Hatse S; Naesens L; Degrève B; Segers C; Vandeputte M; Waer M; De Clercq E; Balzarini J
Int J Cancer; 1998 May; 76(4):595-600. PubMed ID: 9590139
[TBL] [Abstract][Full Text] [Related]
15. Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir).
Zídek Z; Franková D; Holý A
Eur J Pharmacol; 1999 Jul; 376(1-2):91-100. PubMed ID: 10440094
[TBL] [Abstract][Full Text] [Related]
16. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil.
Annaert P; Tukker JJ; van Gelder J; Naesens L; de Clercq E; van Den Mooter G; Kinget R; Augustijns P
J Pharm Sci; 2000 Aug; 89(8):1054-62. PubMed ID: 10906729
[TBL] [Abstract][Full Text] [Related]
17. Adefovir dipivoxil in the treatment of chronic hepatitis B.
Rivkin AM
Ann Pharmacother; 2004 Apr; 38(4):625-33. PubMed ID: 14990784
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of antiviral acyclic nucleoside phosphonate 9-[2-(phosphonomethoxy)ethyl]adenine (adefovir) on cytochrome P450 system of rat liver microsomes.
Zídek Z; Anzenbacher P; Anzenbacherová E; Buchar E; Kmonícková E; Potmesil P; Holý A
J Biomed Sci; 2006 May; 13(3):295-301. PubMed ID: 16416053
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
[TBL] [Abstract][Full Text] [Related]
20. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
